3
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
15
Prostatic Neoplasms
9
Colorectal Neoplasms
7
Ovarian Neoplasms
5
Endometrial Neoplasms
5
Colonic Neoplasms
5
Rectal Neoplasms
4
Colorectal Neoplasms, Hereditary Nonpolyposis
4
Pancreatic Neoplasms
3
Leukemia, Myeloid, Acute
3
Brain Neoplasms
3
Urogenital Neoplasms
2
Neoplastic Syndromes, Hereditary
2
Neoplasms, Unknown Primary
2
Neoplasm Metastasis
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Monocytic, Acute
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Leukemia, Eosinophilic, Acute
2
Leukemia, Basophilic, Acute
2
Leukemia
2
Hereditary Breast and Ovarian Cancer Syndrome
2
Hematologic Neoplasms
2
Glioma
2
Carcinoma, Intraductal, Noninfiltrating
2
Women Age 35+ Qualifies if >15% Lifetime Risk of Breast Cancer as Defined by IBIS Version 8
1
Tuberous Sclerosis
1
Thyroid Neoplasms
1
Spinal Cord Neoplasms
1
Interventions
Exercise
4
Cholecalciferol
4
Nutrition Assessment
3
Gonadotropin-Releasing Hormone
3
Blood Pressure
3
Atorvastatin
3
palbociclib
2
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
2
acalabrutinib
2
Vitamin E
2
Social Determinants of Health
2
Rosuvastatin Calcium
2
Metformin
2
Geritol
2
Fish Oils
2
Fatty Acids, Omega-3
2
Ethanol
2
Electrocardiography
2
Educational Status
2
Echocardiography
2
Diet, Mediterranean
2
Blood Specimen Collection
2
Aspirin
2
Antineoplastic Agents
2
Absorptiometry, Photon
2
zanubrutinib
1
xinmailong
1
ribociclib
1
phosphoribosylformylglycinamidine synthetase
1
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Cardiovascular Diseases
×
Genetic Testing
×
Clear all
NCT02485626
2016-10-31
HARBOR
The Netherlands Cancer Institute
Unknown
628 enrolled